Anthrax vaccine developer PharmAthene is to merge with antibody-focused biotech Theraclone Sciences. PharmAthene said the combined company will have four clinical-stage products, giving it the diversified portfolio desired by management. Article
Anthrax vaccine developer PharmAthene is to merge with antibody-focused biotech Theraclone Sciences. PharmAthene said the combined company will have four clinical-stage products, giving it the diversified portfolio desired by management. Article